Advertisement

Advertisement

ANIP Stock Latest News

ANI Pharmaceuticals initiated with an Outperform at Leerink

The FlyANI Pharmaceuticals initiated with an Outperform at Leerink

ANI Pharmaceuticals reshapes board to advance rare disease strategy

PremiumCompany Announcements

ANI Pharmaceuticals reshapes board to advance rare disease strategy

21d ago

ANI Pharmaceuticals Earnings Call Signals Growth Momentum

PremiumCompany Announcements

ANI Pharmaceuticals Earnings Call Signals Growth Momentum

27d ago

ANI Pharmaceuticals price target lowered to $119 from $124 at Guggenheim

PremiumThe Fly

ANI Pharmaceuticals price target lowered to $119 from $124 at Guggenheim

1M ago

ANI Pharmaceuticals price target lowered to $90 from $91 at Canaccord

PremiumThe Fly

ANI Pharmaceuticals price target lowered to $90 from $91 at Canaccord

1M ago

ANI Pharmaceuticals Posts Record Q2 2026 Results

PremiumCompany AnnouncementsANI Pharmaceuticals Posts Record Q2 2026 Results

1M ago

ANI Pharmaceuticals reports Q2 adjusted EPS $2.21, consensus $2.04

The Fly

ANI Pharmaceuticals reports Q2 adjusted EPS $2.21, consensus $2.04

1M ago

ANI Pharmaceuticals backs FY26 revenue view $1.08B-$1.14B, consensus $1.12B

The Fly

ANI Pharmaceuticals backs FY26 revenue view $1.08B-$1.14B, consensus $1.12B

1M ago

ANI Pharmaceuticals backs FY26 adjusted EPS view $9.19-$9.69, consensus $9.42

PremiumThe Fly

ANI Pharmaceuticals backs FY26 adjusted EPS view $9.19-$9.69, consensus $9.42

1M ago

ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

1M ago

ANI Pharmaceuticals initiated with a Hold at Canaccord

PremiumThe Fly

ANI Pharmaceuticals initiated with a Hold at Canaccord

2M ago

ANI Pharmaceuticals intends to appeal rulings in CG Oncology matter

PremiumThe Fly

ANI Pharmaceuticals intends to appeal rulings in CG Oncology matter

2M ago

ANI Pharmaceuticals initiated with a Hold at Canaccord

PremiumThe FlyANI Pharmaceuticals initiated with a Hold at Canaccord

2M ago

Buy Rating Reaffirmed on Cortrophin Strength and ILUVIEN Upside; $121 Price Target Maintained

Ratings

Buy Rating Reaffirmed on Cortrophin Strength and ILUVIEN Upside; $121 Price Target Maintained

2M ago

ANI Pharmaceuticals reports ‘positive’ results from Phase 4 Synchronicity trial

The Fly

ANI Pharmaceuticals reports ‘positive’ results from Phase 4 Synchronicity trial

2M ago

ANI Pharmaceuticals Signals Confident 2026 Growth Path

PremiumCompany Announcements

ANI Pharmaceuticals Signals Confident 2026 Growth Path

3M ago

ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan

PremiumCompany Announcements

ANI Pharmaceuticals Shareholders Approve Amended 2022 Incentive Plan

4M ago

ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics

PremiumCompany Announcements

ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics

4M ago

Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum

PremiumRatings

Analyst Reiterates Buy Rating After Earnings Beat and Raised Full-Year Guidance on Strong Cortrophin Gel Momentum

4M ago

ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30

PremiumThe FlyANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30

4M ago

ANI raises FY26 adjusted EPS view to $9.19-$9.69 from $8.83-$9.34

The Fly

ANI raises FY26 adjusted EPS view to $9.19-$9.69 from $8.83-$9.34

4M ago

ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pre-Earnings

ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >